UPDATE ON DEMENTIA WITH LEWY BODIES.
Dementia with Lewy bodies (DLB) is the second most common form of dementia after Alzheimer disease (AD). DLB is characterized pathologically by Lewy body and Lewy neuritic pathology, often with variable levels of Alzheimer-type pathology. Core clinical features include fluctuating cognition, visual hallucinations, and parkinsonism resulting in greater impairments of quality of life, more caregiver burden, and higher health-related costs compared with AD. These issues, together with a high sensitivity to adverse events with treatment with antipsychotic agents, make the need for an early and accurate diagnosis of DLB essential. Unfortunately, current consensus criteria are highly specific but lack sufficient sensitivity. Use of composite risk scores may improve accuracy of clinical diagnosis. Imaging findings, particularly targeting dopaminergic systems have shown promise as potential markers to differentiate DLB from AD. A combination of non-pharmacologic treatments and pharmacotherapy interventions may maximize cognitive function and overall quality of life in DLB patients.
Comprehensive Center on Brain Aging and Department of Neurology, New York University Langone Medical Center, NY, USA.
Stella
S
Karantzoulis
Comprehensive Center on Brain Aging and Departments of Neurology and Psychiatry, New York University Langone Medical Center, NY, USA.
James E
JE
Galvin
Aging; Alzheimer’s disease; Biomarkers; Dementia with Lewy bodies; Genetics; Lewy bodies; Neuroimaging; Neuropathology; Parkinson’s disease; Risk Scores; Therapeutics